The FDA has authorized urcosimod 0.05% for single-patient expanded access, or compassionate use, in a patient with ...
AI has the potential to transform cataract surgery outcomes for the better, according to a speaker. Surgical planning, predictive analytics for patient recovery and postoperative assessments are a few ...
From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua ...